Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03718910 · ClinicalTrials.gov registry record

DDX3X Syndrome -The Seaver Autism Center for Research and Treatment is Characterizing DDX3X-related Neurodevelopmental Disorders Using Genetic, Medical, and Neuropsychological Measures.

A clinical trial of Autism Spectrum Disorder and DDX3X, sponsored by Icahn School of Medicine at Mount Sinai.

Recruiting
Registry status
10
Enrollment target
1
Study location

NCT03718910 is a study of Autism Spectrum Disorder and DDX3X that is actively recruiting participants, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 10 participants, below the 135-participant average among 224 other Autism Spectrum Disorder trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03718910, a study of Autism Spectrum Disorder and DDX3X, is actively recruiting participants, sponsored by Icahn School of Medicine at Mount Sinai.

RECRUITING
Registry status
10 participants
Enrollment target
1
Study location

Study Summary

DDX3X syndrome is a genetic cause of intellectual disability and other neurologic features including, in some cases, autism. Variants in the DDX3X gene are thought to account for 1-3% of unexplained intellectual disability in females, making it one of the more common causes of intellectual disability.This study seeks to characterize DDX3X-related neurodevelopmental disorders using a number of genetic, medical and neuropsychological measures.

Study Locations (1)

New York

  • The Seaver Autism Center for Research and Treatment - New York

Trial Details

FieldValue
Enrollment Target 10 participants
Start Date 2018-05-22
Est. Completion 2026-05

What the Registry Record Tells You About NCT03718910

The ClinicalTrials.gov registry entry for NCT03718910 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 135-participant average among 224 other Autism Spectrum Disorder trials with a reported enrollment target (93% lower). The listed sponsor is Icahn School of Medicine at Mount Sinai, which has 708 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Autism Spectrum Disorder appearing as the primary indexed condition, and to 0 interventions.

NCT03718910 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT03718910 about?

NCT03718910 is a clinical study titled "DDX3X Syndrome -The Seaver Autism Center for Research and Treatment is Characterizing DDX3X-related Neurodevelopmental Disorders Using Genetic, Medical, and Neuropsychological Measures.". DDX3X syndrome is a genetic cause of intellectual disability and other neurologic features including, in some cases, autism. Variants in the DDX3X gene are thought to account for 1-3% of unexplained intellectual disability in females, making it one of the more common causes of intellectual disabilit...

What is the current status of trial NCT03718910?

This trial is currently recruiting. The enrollment target is 10 participants. The study started on 2018-05-22. Estimated completion is 2026-05.

What conditions does trial NCT03718910 study?

This clinical trial studies the following conditions: Autism Spectrum Disorder, DDX3X, Mental Retardation, X-linked 102.

Who is sponsoring clinical trial NCT03718910?

This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03718910 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Autism Spectrum Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.